18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer

Launched by VA GREATER LOS ANGELES HEALTHCARE SYSTEM · Nov 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a specific imaging test called 18F-Fluciclovine PET/CT can help predict how well a treatment called Lutetium-PSMA-617 therapy works for men with advanced prostate cancer that no longer responds to hormone therapy. The trial is taking place at the West Los Angeles VA and is open only to veterans. Participants must be males aged 65 to 74 who are scheduled to receive this treatment and are willing to undergo several imaging scans before and after the therapy.

If you participate in this study, you will have multiple PET/CT scans to monitor your condition—one before starting the treatment and more after the second, fourth, and sixth cycles of therapy. These scans help doctors see how your cancer is responding to the treatment. It's important to know that you must be able to provide written consent and have no serious medical issues that would interfere with the study. This trial aims to improve understanding of how imaging can guide treatment decisions for prostate cancer patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Patients with mCRPC scheduled to undergo LuPSMA RLT.
• • Willingness to undergo multiple serial PET/CT scans pre- and post-LuPSMA RLT.
• • Ability of providing written informed consent.
• Exclusion Criteria:
• • Less than 18 years-old at the time of radiopharmaceutical administration.
• • Medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study procedures or compliance.
• • Contraindications to LuPSMA RLT.